The global marine-derived pharmaceuticals market size was estimated to be US$ 1.7 billion in 2021 and is expected to grow at a CAGR of 7.2% between 2023 to 2032.
Newly emerging diseases are rapidly evolving due to environmental conditions and the increased human population. This is causing an increase in the burden for existing resources and treatments. Pharmaceutical companies are constantly trying to find new compounds and drugs to tackle bacterial, viral, and cancerous diseases.
The marine environment has shown great potential for the availability and discovery of new bioactive compounds. Marine-derived drugs have therefore become a rising source of safe and effective drugs. The reason the marine ecosystem has vast potential is that it has the most diverse phyla of organisms with special biological pathways that generate millions of unique biomolecules.
Several animal and plant species have been used to generate compounds that have anti-viral, anti-bacterial, anti-cancerous, and neuroprotective properties. The emergence of these new drugs coupled with special research interest in the marine field has the potential to positively impact the global marine-derived pharmaceutical market in the upcoming decades.
The main sources currently used for bioactive compounds and proteins are algae, fish, crabs, and marine bacteria. The main usage of marine derived drugs has been for infectious diseases along with anti-cancer treatments. There is a prospective growth forecast in the same sectors for the studied period.
Although marine derived drugs have been used in treatments throughout human history, their growth is gaining speed in recent years. Rich molecular diversity, novel treatment opportunities, rising efficacy, and increased awareness have enabled fast-paced growth in marine drug development and research. Increased research and development are also fueled by increased global funding for such endeavours as well as the patentability of such novel drugs.
As mentioned earlier, major segments seeing exponential growth in the marine derived pharmaceutical markets are oncology treatment and anti-infection medications. Cancer has become one of the leading causes of death across the world within the past several years. This rise is naturally due to the growing population and survival ratio as compared to other diseases. The increased demand for novel treatments or co-therapies has fuelled a search for new compounds against all major types of cancer. This drives the market for marine-derived pharmaceuticals towards record-breaking sales of newly formulated marine drugs.
Another segment with novel therapeutic value is the marine peptide market with very high potential, if not immediately but at least in coming years. These marine peptides have various physiological benefits and can be used as biosimilars, antibiotics, or nutrient sources. Nutrient supplement sales have seen better results due to notable benefits like fewer R&D requirements and fewer regulations compared to drugs and treatments.
There exists a vast number of players trying to explore the untapped chemical resources available from the marine ecosystem. All major companies and research facilities are investing in R&D activities for marine-derived pharmaceuticals globally. This in turn has resulted in a better output of breakthrough drugs and treatments increasing growth rate and awareness. New collaborations, revenue generation strategies, and quicker adoption have increased the scope of the global marine-derived pharmaceutical market.
Strategic collaborations are expected to be a key factor in new developments across the marine drugs sector. Increased mergers, acquisitions, and joint ventures will enable big players to increase their dominance and subsequent growth of marine-derived pharmaceuticals.
Licensing agreements will also drive revenue growth by increasing outreach of existing and approved drugs throughout the globe. Tremendous opportunities are being expected through tie-ups, marketing, and competitive pressures for the dissemination of knowledge and research in marine drugs. We have a detailed report on the global marine derived pharmaceuticals market that provides insights into relevant partnerships, research gaps, and clinical testing pipelines.
The major hurdles present in the overall growth prospect of marine drug markets are the limited supply of organisms and raw materials. Several species used for drug extraction are rare to find or have culturing difficulties. This reduced availability of animals results in an appreciation of cost and final product price. Price-sensitive markets or drugs with high demand have faced hindrances due to such constraints.
Developing in-vitro or cellular processes for the production of such marine derived drugs will be a necessary first step to address this concern. Several attempts are being made to the production of approved drugs with varying levels of success.
Tackling the above challenges, however, will not be enough as technological hurdles in extraction and preservation also have a deep impact on drug availability. General problems and challenges in the development of economical and eco-friendly supply chains faced by the pharmaceutical industry at large are also creating a hurdle in the growth of the global marine derived pharmaceutical market.
The covid-19 pandemic also created a negative impact on regional pharmaceutical products across the globe. The increased strain on the supply chain, reduced availability of raw materials, and lockdown-related problems impacted the marine-derived drugs development more than terrestrial and micro-organism-derived drugs.
Normalization of these constraints has however enabled a resurgence of marine drug development and clinical testing. Leaders and big companies involved in the marine derived pharmaceutical market should focus on fast-growing segments for sales, and explore new segments for discovering novel marine drugs.
The North America region has a third of the global marine derived pharmaceutical market and will show significant growth across the forecast period of the next decade. The United States and Canada are the largest markets for experimental and approved marine pharmaceutical products. Marine-derived drugs market growth in this region along with Europe and Asia will be better compared to the rest of the world for the next several years.
Key companies involved in the development and sale of marine-derived pharmaceuticals are Amway Corp., BASF SE, BioMarin Pharmaceutical inc., GlaxoSmithKline Plc, Guardian Industries Corp., Koninklijke DSM NV, Pfizer Inc., Pharma Marine AS, Seagen Inc., etc.
By Product type
By End users
The marine-derived pharmaceuticals market is expected grow at a CAGR of 7.2% from 2023 to 2032.
Increased burden for existing resources and treatments and a large availability of undiscovered chemicals with unique activity are driving research and growth in the marine-derived drugs market.
Companies majorly involved in the development and sale of marine-derived pharmaceuticals are Amway Corp., BASF SE, BioMarin Pharmaceutical inc., GlaxoSmithKline Plc, Guardian Industries Corp., Koninklijke DSM NV, Pfizer Inc., Pharma Marine AS, Seagen Inc., etc.
The North America region has a third of the global marine derived pharmaceutical market and will show significant growth across the forecast period of the next decade. The United States and Canada are the largest markets for experimental and approved marine pharmaceutical products.
As mentioned earlier, major segments seeing exponential growth in the marine derived pharmaceutical markets are oncology treatment and anti-infection medications.
Based on activity, the marine derived pharmaceuticals market is segmented into Cancer treatment, Antibiotic, Nutritional and others.
Marine derived pharmaceuticals are bioactive compounds that are extracted from animals or plants of marine environment.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved